POS0200 TYPE I INTERFERON ACTIVITY IN PERSISTENTLY ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PATIENTS WITH OR WITHOUT LUPUS: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)
Romy Kallas(Hospital for Special Surgery), Doruk Erkan(Hospital for Special Surgery), Nina Kello(Northwell Health), Alí Duarte‐García(Mayo Clinic in Arizona), María Laura Bertolaccini(St Thomas' Hospital), D. Jannat-Khah(Hospital for Special Surgery), H. Michael Belmont(New York University), Rohan Willis(The University of Texas Medical Branch at Galveston), D. Ware Branch(University of Utah), Hannah Cohen(University College London Hospitals NHS Foundation Trust), Paul R. Fortin(Centre hospitalier de l'Université Laval), Michelle Petri(Johns Hopkins University), Jason S. Knight(University of Michigan), Andrra Nimoni(Hospital for Special Surgery), Megan R.W. Barber(University of Calgary), N.M. Piatchou Donfack(Hospital for Special Surgery), Théo Niewold(Schothorst Feed Research)
Cited by 0
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840